Additionally, IL-5, which is associated with eosinophilia and VLS induced by high-dose IL-2, did not significantly change in response to SAR’245 treatment alone or in combination with pembrolizumab or nivolumab (8). This evidence concerns the gene IL2 and Increased total eosinophil count.